Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Elutia Yönetim

Yönetim kriter kontrolleri 3/4

Elutia's CEO'su Randy Mills, Jun2022 tarihinde atandı, in görev süresi 2.33 yıldır. in toplam yıllık tazminatı $ 2.05M olup, şirket hissesi ve opsiyonları dahil olmak üzere 29.3% maaş ve 70.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.75% ine doğrudan sahiptir ve bu hisseler $ 967.51K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 6.5 yıldır.

Anahtar bilgiler

Randy Mills

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi	29.3%
CEO görev süresi	2.3yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	6.5yrs

Son yönetim güncellemeleri

Recent updates

Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Jun 28

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Mar 10

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Feb 21

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Apr 17

Aziyo Biologics appoints Williams as Chief Scientific Officer

Aug 26

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aug 10

CEO Tazminat Analizi

Randy Mills'un ücretlendirmesi Elutia'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$70m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$2m	US$600k	-US$41m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$35m
Mar 31 2023	n/a	n/a	-US$38m
Dec 31 2022	US$2m	US$321k	-US$36m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$37m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$146k	n/a	-US$25m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	n/a	n/a	-US$26m
Dec 31 2020	US$142k	n/a	-US$25m

Tazminat ve Piyasa: Randy 'nin toplam tazminatı ($USD 2.05M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Randy 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Randy Mills (52 yo)

2.3yrs

Görev süresi

US$2,050,887

Tazminat

Dr. C. Randal Mills, Ph D., also known as Randy, has been Director of Elutia Inc. (formerly known as Aziyo Biologics, Inc.) since November 2015. Dr. Mills serves as a Member of Advisory Board at eXpanded e...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
C. Mills	Co-Founder	2.3yrs	US$2.05m	0.75% $ 967.5k
Matthew Ferguson	Chief Financial Officer	4.1yrs	US$521.08k	0.91% $ 1.2m
Michelle Williams	Chief Scientific Officer	2.2yrs	US$485.97k	0.18% $ 228.0k
Erica Elchin	Vice President of Global Operations	2yrs	Veri yok	Veri yok
Courtney Guyer	Vice President of Marketing	6.8yrs	Veri yok	Veri yok
Sonali Fonseca	VP & Head of Emerging Businesses	2.8yrs	Veri yok	Veri yok
Jeffry Hamet	Senior VP of Finance	no data	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: ELUT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
C. Mills	Co-Founder	8.9yrs	US$2.05m	0.75% $ 967.5k
Kevin Rakin	Independent Chairman & Lead Independent Director	8.9yrs	US$254.61k	0.27% $ 346.0k
Brigid Makes	Independent Director	4.1yrs	US$116.41k	0.0059% $ 7.6k
Matt Zuga	Independent Director	8.9yrs	US$80.99k	0% $ 0
Maybelle Jordan	Independent Director	4.1yrs	US$96.41k	0% $ 0
David Colpman	Independent Director	2yrs	US$93.91k	0% $ 0

6.5yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ELUT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.5 yıldır).

Elutia Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Financial Officer exercised options to buy US$359k worth of stock.

Co-Founder exercised options and sold US$67k worth of stock

Elutia Inc., Annual General Meeting, Jun 06, 2024

Aziyo Biologics, Inc. Appoints David Colpman to Board of Directors and Audit Committee

Aziyo Biologics, Inc. Promotes Jeff Hamet to Senior Vice President of Finance

Aziyo Biologics, Inc. Appoints Michelle Leroux Williams, Ph.D as Chief Scientific Officer

Recent updates

Elutia Inc. Announces New Peer Reviewed Publication Highlighting the Robustness of Elupro™, Company’S Antibiotic-Eluting Bioenvelope for Implantable Devices

Consensus EPS estimates fall by 71%

New major risk - Financial position

New major risk - Share price stability

New minor risk - Market cap size

Chief Financial Officer exercised options to buy US$359k worth of stock.

Elutia Inc. to Report Q2, 2024 Results on Aug 07, 2024

Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

New major risk - Shareholder dilution

Price target increased by 60% to US$8.00

Elutia Inc. Announces FDA Clearance of EluPro®

Co-Founder exercised options and sold US$67k worth of stock

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Elutia Inc. to Report Q1, 2024 Results on May 09, 2024

New major risk - Shareholder dilution

Elutia Inc., Annual General Meeting, Jun 06, 2024

New major risk - Shareholder dilution

News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Elutia Inc. to Report Q4, 2023 Results on Mar 07, 2024

Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues

Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance

Consensus revenue estimates increase by 17%

Elutia Notifies the Nasdaq Stock Market LLLC That the Company Was Not in Compliance with Listing Rule 5605(B)(1)

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT).

Elutia Inc. Receives A Delisting Determination Letter from Listing Qualifications Department of Nasdaq

Elutia Inc. to Report Q3, 2023 Results on Nov 13, 2023

Elutia Inc. announced that it has received $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC

New major risk - Shareholder dilution

Berkeley Biologics, LLC entered into an Asset Purchase Agreement Orthobiologics business unit of Elutia Inc. (NasdaqCM:ELUT) for $35 million.

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates decrease by 25%, EPS upgraded

Aziyo Biologics, Inc. Announces the Voluntary Recall of Its Viable Bone Matrix Products

Price target decreased by 17% to US$10.00

Aziyo Biologics, Inc. Presents Positive Clinical Data on Cangaroo® Biologic Envelope

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.60 loss in 1Q 2022)

Aziyo Biologics, Inc. to Report Q1, 2023 Results on May 10, 2023

Little Excitement Around Aziyo Biologics, Inc.'s (NASDAQ:AZYO) Revenues As Shares Take 63% Pounding

Full year 2022 earnings released

Aziyo Biologics, Inc. Provides Preliminary Sales Guidance for the Fourth Quarter and Full Year 2022

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. has completed a Follow-on Equity Offering in the amount of $11.1625 million.

Aziyo Biologics, Inc. Revises Revenue Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Aziyo Biologics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Aziyo Biologics, Inc. Appoints David Colpman to Board of Directors and Audit Committee

Aziyo Biologics, Inc. Promotes Jeff Hamet to Senior Vice President of Finance

Aziyo Biologics, Inc. Appoints Michelle Leroux Williams, Ph.D as Chief Scientific Officer

Aziyo Biologics appoints Williams as Chief Scientific Officer

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Announces Randal Mills as Chief Executive Officer

Aziyo Biologics names co-founder C. Randal Mills as permanent CEO

Aziyo Biologics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Aziyo Biologics, Inc. Appoints C. Randal (Randy) Mills, Ph.D. as Interim President

Aziyo Biologics Receives a Written Notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aziyo Biologics, Inc. Confirms Financial Guidance for Year 2022

Price target decreased to US$13.00

Aziyo Biologics, Inc. to Report Q1, 2022 Results on May 09, 2022

Aziyo Biologics, Inc., Annual General Meeting, Jun 07, 2022

Aziyo Biologics, Inc. Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics

Consensus EPS estimates fall by 10%

CEO Tazminat Analizi

CEO